文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

评估新获批药物用于耐多药结核的endTB试验:自适应多国随机对照试验方案

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
PubMed 文献 · Trials · 2021-09-25

endTB是一项III期、实用性、多国、自适应、随机对照、平行、开放标签临床试验,评估含新药的较短方案治疗氟喹诺酮敏感、利福平耐药结核的疗效与安全性。受试者随机分配至对照组或五种含新获批及老药新用药物的39周多药方案组。主要目的是评估试验方案73周时疗效是否非劣效于对照。

要点

  • endTB试验评估五种含新药的39周方案治疗氟喹诺酮敏感利福平耐药结核。
  • 采用贝叶斯期中分析进行响应自适应随机化。
  • 样本量750例、6组,非劣效界值12%,单侧α=0.025,把握度至少80%。

核心结论

  • 需要高质量证据评估含新药的更短、安全有效方案,以减轻耐多药/利福平耐药结核的疾病负担。

研究设计与样本

  • endTB为III期、实用性、多国、自适应、随机对照、平行、开放标签临床试验。
  • 受试者为氟喹诺酮敏感、利福平耐药结核患者。
  • 样本量750例,随机分配至6个臂,包括对照组和五个39周多药方案组。
  • 随机化采用基于疗效终点贝叶斯期中分析的响应自适应设计。
  • 参与时间从随机化后至少73周至多104周。

关键数值与推荐

  • 主要目的为评估试验方案73周时疗效是否非劣效于对照。
  • 非劣效界值为12%,单侧α=0.025。
  • 样本量750例、6臂提供至少80%把握度检测至少1个(至多3个)试验方案的非劣效性。
  • 分析人群包括改良意向治疗和符合方案人群。

临床怎么用

  • 若证实非劣效,含新药的较短全口服方案可能扩展治疗选择。

局限性

  • 开放标签设计可能引入偏倚。
  • 结果尚未报告,方案尚待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A shorter all-oral regimen is currently recommended for only a sub-set of MDR/RR-TB. Its use is only conditionally recommended because of very low-quality evidence underpinning the recommendation. Novel combinations of newer and repurposed drugs bring hope in the fight against MDR/RR-TB, but their use has not been optimized in all-oral, shorter regimens. This has greatly limited their impact on the burden of disease. There is, therefore, dire need for high-quality evidence on the performance of new, shortened, injectable-sparing regimens for MDR-TB which can be adapted to individual patients and different settings. METHODS: endTB is a phase III, pragmatic, multi-country, adaptive, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of shorter treatment regimens containing new drugs for patients with fluoroquinolone-susceptible, rifampin-resistant tuberculosis. Study participants are randomized to either the control arm, based on the current standard of care for MDR/RR-TB, or to one of five 39-week multi-drug regimens containing newly approved and repurposed drugs. Study participation in all arms lasts at least 73 and up to 104 weeks post-randomization. Randomization is response-adapted using interim Bayesian analysis of efficacy endpoints. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 750 patients across 6 arms affords at least 80% power to detect the non-inferiority of at least 1 (and up to 3) experimental regimens, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per protocol populations. DISCUSSION: The lack of a safe and effective regimen that can be used in all patients is a major obstacle to delivering appropriate treatment to all patients with active MDR/RR-TB. Identifying multiple shorter, safe, and effective regimens has the potential to greatly reduce the burden of this deadly disease worldwide. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02754765. Registered on 28 April 2016; the record was last updated for study protocol version 3.3, on 27 August 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Guglielmetti L, Ardizzoni E, Atger M, et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021. PMID: 34563240. doi:10.1186/s13063-021-05491-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。